BEAMHealthcare · BiotechnologyThe 15 Wall Street analysts covering Beam Therapeutics, Inc. hold a median 12-month price target of $45 — +51.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Beam Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BEAM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +51.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 July 2026 | B of A Securities | Reiterates | Buy | $47 |
| 7 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $80 |
| 13 May 2026 | Bernstein | Maintains | Outperform | — |
| 26 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Feb 2026 | RBC Capital | Maintains | Sector Perform | — |
| 25 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 20 Feb 2026 | Canaccord Genuity | Initiates | Buy | — |
| 21 Jan 2026 | Bernstein | Maintains | Outperform | — |
| 7 Jan 2026 | UBS | Initiates | Neutral | — |
| 24 Nov 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 10 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Oct 2025 | JP Morgan | Maintains | Overweight | — |
| 15 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2025 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2025 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2025 | Guggenheim | Maintains | Buy | — |
| 7 May 2025 | Wells Fargo | Maintains | Overweight | — |
| 7 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2025 | B of A Securities | Upgrade | Buy | — |
| 12 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BEAM appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 10% of US stocks
Cheaper than 37% of US stocks
Cheaper than 79% of US stocks
Higher than 2% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 9% of US stocks
Higher than 37% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Beam Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Beam Therapeutics reported a wider-than-expected Q2 loss and revenues that fell short of estimates, while continuing to advance its genome-editing pipeline toward key clinical milestones.
Why it matters — The wider loss and revenue miss could raise concerns about the company's financial performance even as its pipeline progress remains a focus for investors.
Beam Therapeutics reported a second-quarter loss of $1.18 per share, wider than the Zacks Consensus Estimate of a $1 per-share loss and a year-ago loss of $1 per share. The report also lagged revenue estimates according to the headline.
Why it matters — The quarterly loss came in above the consensus estimate, which matters to BEAM watchers as a miss on expectations.
Beam Therapeutics reported its second quarter 2026 financial results and announced that the first patient has been dosed in the global pivotal cohort of the BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD). Separately, updated BEAM-302 Phase 1/2 clinical data were selected for a late-breaking oral presentation at the ERS Congress 2026.
Why it matters — A BEAM watcher would care because the BEAM-302 program is advancing into its pivotal phase and receiving prominent presentation at a major respiratory congress, signaling progress in the AATD pipeline.
Seeking Alpha published a valuation analysis of Beam Therapeutics, citing its $2.64B market cap and a gene-editing pipeline covering hematology and liver-targeted diseases. The piece highlights lead programs Risto-cel, BEAM-302, and BEAM-301, as well as the company's $1.2B liquidity providing a cash runway into 2029, supplemented by collaboration revenue from Eli Lilly and Pfizer.
Why it matters — BEAM watchers would note the article's view that the company's pipeline shows competitive efficacy and safety with ample funding, which bears on its longer-term commercial potential.
The 15 Wall Street analysts covering Beam Therapeutics, Inc. have a median 12-month price target of $45, with estimates ranging from $26 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Beam Therapeutics, Inc., 13 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beam Therapeutics, Inc. 47 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Beam Therapeutics, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +51.2% from the last close, and Ticker Nerd's factor model ranks Beam Therapeutics, Inc. 47 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Beam Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BEAM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $80 over the next 12 months.
Beam Therapeutics, Inc. returned +85.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using base editing technology.
The most recent item we track (Zacks Investment Research, 5 Aug 2026): "BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus". Beam Therapeutics reported a wider-than-expected Q2 loss and revenues that fell short of estimates, while continuing to advance its genome-editing pipeline toward key clinical milestones.
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using base editing technology. The company designs therapies that aim to make targeted, single-base changes in DNA or RNA, with the goal of precisely correcting disease-causing mutations at the molecular level. Beam Therapeutics Inc. concentrates on serious conditions across areas such as hematology, liver and metabolic disorders, oncology, and genetic diseases, advancing a pipeline that includes programs like BEAM-101, BEAM-201, BEAM-301, and BEAM-302, as well as its ESCAPE platform for engineered stem cell therapies. Its business model centers on proprietary editing platforms, internal drug discovery, and strategic collaborations with larger pharmaceutical and biotechnology companies to co-develop or outlicense selected programs. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam Therapeutics Inc. plays a specialized role in the health technology and biotechnology sectors by providing tools and candidate therapies that support the broader shift toward highly targeted, mechanism-based treatments.
CEO Mr. John M. Evans M.B.A. · 540 employees · United States · https://beamtx.com